INO-8875: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 11610599 |
| CHEMBL ID | 3545407 |
| SCHEMBL ID | 121828 |
| MeSH ID | M0581649 |
| Synonym |
|---|
| trabodenoson (usan/inn) |
| D10493 |
| inno 8875 |
| n6-cyclopentyladenosine 5'-nitrate |
| unii-1t237110w4 |
| pj 875 |
| 871108-05-3 |
| 1t237110w4 , |
| trabodenoson [usan:inn] |
| trabodenoson |
| inno-8875 |
| n-cyclopentyladenosine 5'-nitrate |
| us8470800, a |
| us8609833, 17 |
| bdbm97464 |
| pj-875 |
| trabodenoson [usan] |
| trabodenoson [inn] |
| SCHEMBL121828 |
| us8609833, 86 |
| bdbm108255 |
| DTXSID90236139 |
| CHEMBL3545407 |
| ino-8875 |
| ((2r,3s,4r,5r)-5-(6-(cyclopentylamino)-9h-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl nitrate |
| AKOS027337131 |
| mfcd28502082 |
| AS-52370 |
| DB13122 |
| Q27252846 |
| P14975 |
| HY-106007 |
| [(2r,3s,4r,5r)-5-[6-(cyclopentylamino)purin-9-yl]-3,4-dihydroxyoxolan-2-yl]methyl nitrate |
| CS-0024616 |
| AKOS040754236 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Dose-response experiments in the isolated hearts of rats were used to evaluate the functional selectivity of INO-8875 for the slowing of A-V-nodal conduction." | ( INO-8875, a highly selective A1 adenosine receptor agonist: evaluation of chronotropic, dromotropic, and hemodynamic effects in rats. Beharier, O; Dror, S; Etzion, Y; Katz, A; Mor, M; Moran, A; Pikovsky, O; Shalev, A, 2013) | 2.04 |
| " Its Phase 3 pivotal clinical trials failed at the wrong dose and dosing regimen because of the misinterpretation of the complex IOP results from the Phase 2 monotherapy and combination studies." | ( Trabodenoson on trabecular meshwork rejuvenation: a comprehensive review of clinical data. Qiu, TG, 2021) | 0.62 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Adenosine receptor A1 | Homo sapiens (human) | Ki | 0.0010 | 0.0002 | 0.9316 | 10.0000 | AID1280098; AID1674165 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| G protein-coupled receptor binding | Adenosine receptor A1 | Homo sapiens (human) |
| purine nucleoside binding | Adenosine receptor A1 | Homo sapiens (human) |
| protein binding | Adenosine receptor A1 | Homo sapiens (human) |
| heat shock protein binding | Adenosine receptor A1 | Homo sapiens (human) |
| G-protein beta/gamma-subunit complex binding | Adenosine receptor A1 | Homo sapiens (human) |
| heterotrimeric G-protein binding | Adenosine receptor A1 | Homo sapiens (human) |
| protein heterodimerization activity | Adenosine receptor A1 | Homo sapiens (human) |
| G protein-coupled adenosine receptor activity | Adenosine receptor A1 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| plasma membrane | Adenosine receptor A1 | Homo sapiens (human) |
| plasma membrane | Adenosine receptor A1 | Homo sapiens (human) |
| basolateral plasma membrane | Adenosine receptor A1 | Homo sapiens (human) |
| axolemma | Adenosine receptor A1 | Homo sapiens (human) |
| asymmetric synapse | Adenosine receptor A1 | Homo sapiens (human) |
| presynaptic membrane | Adenosine receptor A1 | Homo sapiens (human) |
| neuronal cell body | Adenosine receptor A1 | Homo sapiens (human) |
| terminal bouton | Adenosine receptor A1 | Homo sapiens (human) |
| dendritic spine | Adenosine receptor A1 | Homo sapiens (human) |
| calyx of Held | Adenosine receptor A1 | Homo sapiens (human) |
| postsynaptic membrane | Adenosine receptor A1 | Homo sapiens (human) |
| presynaptic active zone | Adenosine receptor A1 | Homo sapiens (human) |
| synapse | Adenosine receptor A1 | Homo sapiens (human) |
| dendrite | Adenosine receptor A1 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1674165 | Binding affinity to A1 receptor (unknown origin) | 2020 | Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19 | Ocular Disease Therapeutics: Design and Delivery of Drugs for Diseases of the Eye. |
| AID1280098 | Binding affinity to adenosine A1 receptor (unknown origin) | 2016 | Journal of medicinal chemistry, Feb-11, Volume: 59, Issue:3 | Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.25) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (12.50%) | 5.53% |
| Reviews | 3 (37.50%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 4 (50.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||